APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.

MLA

Chen, Mingjue, et al. “APC/PIK3CA Mutations and β-Catenin Status Predict Tankyrase Inhibitor Sensitivity of Patient-Derived Colorectal Cancer Cells.” British Journal of Cancer, vol. 130, no. 1, Jan. 2024, pp. 151–62. EBSCOhost, https://doi.org/10.1038/s41416-023-02484-8.

APA

Chen, M., Mashima, T., Oishi, T., Muramatsu, Y., Seto, Y., Takamatsu, M., Kawata, N., Morino, S., Nakamura, A., Inaba, S., Yuan, X., Maruyama, K., Suzuki, M., Sato, A., Yoshida, H., Jang, M.-K., Mizutani, A., Takeuchi, K., Yamaguchi, K., … Seimiya, H. (2024). APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. British Journal of Cancer, 130(1), 151–162. https://doi.org/10.1038/s41416-023-02484-8

Chicago

Chen, Mingjue, Tetsuo Mashima, Taichi Oishi, Yukiko Muramatsu, Yosuke Seto, Manabu Takamatsu, Naomi Kawata, et al. 2024. “APC/PIK3CA Mutations and β-Catenin Status Predict Tankyrase Inhibitor Sensitivity of Patient-Derived Colorectal Cancer Cells.” British Journal of Cancer 130 (1): 151–62. doi:10.1038/s41416-023-02484-8.